| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
63,780,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $0.94 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile RVL Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patients in the ocular medicine and medical aesthetics therapeutic areas. Co.'s portfolio includes RVL-1201, or Upneeq, (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy or low-lying eyelids in adults. Co. has expanded its commercialization activities among ophthalmology, optometry and oculoplastic specialties. Co. makes Upneeq available through RVL Pharmacy, Inc., its wholly-owned pharmacy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
25,000,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$38,750,000 |
| Total People Bought |
0 |
0 |
0 |
5 |
| Total Buy Transactions |
0 |
0 |
0 |
5 |
| Total Shares Sold |
0 |
0 |
35,088,392 |
35,088,392 |
| Total Sell Value |
$0 |
$0 |
$1,602,356 |
$1,602,356 |
| Total People Sold |
0 |
0 |
2 |
2 |
| Total Sell Transactions |
0 |
0 |
6 |
6 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Devries Tina Marie |
EVP, Research & Development |
• – – |
2021-01-24 |
4 |
D |
$4.46 |
$42,803 |
D/D |
(9,597) |
157,662 |
|
- |
|
| Klein Christopher |
General Counsel & Secretary |
• – – |
2021-01-24 |
4 |
D |
$4.46 |
$42,838 |
D/D |
(9,605) |
217,829 |
|
- |
|
| Cowan Gregory L |
Director |
– • – |
2021-01-24 |
4 |
D |
$4.46 |
$24,552 |
D/D |
(5,505) |
74,145 |
|
- |
|
| Schaub James |
EVP and COO |
• – – |
2021-01-24 |
4 |
D |
$4.46 |
$43,204 |
D/D |
(9,687) |
318,721 |
|
- |
|
| Weiss Fred G |
Director |
– • – |
2021-01-24 |
4 |
D |
$4.46 |
$24,552 |
D/D |
(5,505) |
81,368 |
|
- |
|
| Einhorn Andrew J. |
Chief Financial Officer |
• – – |
2021-01-24 |
4 |
D |
$4.46 |
$43,119 |
D/D |
(9,668) |
157,547 |
|
- |
|
| Burgstahler David F |
Director |
– • • |
2020-11-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,936,926) |
0 |
|
- |
|
| Venkataraman Sriram |
Director |
– • • |
2020-11-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,936,926) |
0 |
|
- |
|
| Orbit Co-Invest Iii Llc |
10% Owner |
– – • |
2020-11-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,936,926) |
0 |
|
- |
|
34 Records found
|
|
Page 2 of 2 |
|
|
